News | Radiation Therapy | November 08, 2022

Elekta’s newest radiosurgery system can now benefit those where FDA clearance is recognized 

Elekta announced that Elekta Esprit, a new Leksell Gamma Knife radiosurgery platform, received FDA 510(k) clearance.

November 8, 2022 — Elekta announced that Elekta Esprit, a new Leksell Gamma Knife radiosurgery platform, received FDA 510(k) clearance. This milestone makes the system available to clinicians and people with brain disease in the U.S., as well as opening the door to other countries where FDA approval is recognized. 

Leksell Gamma Knife has been designed as a gentler alternative to open surgery and conventional radiotherapy. It can target the smallest and most challenging intracranial tumors and lesions with minimal effect on healthy tissue. This vital precision safeguards motor, sensory and neurocognitive function to help protect the mind and the person. 

Verena Schiller, President of Elekta’s Neuroscience Solutions, says: “It’s very inspiring to hear how patients treated with Gamma Knife are able to maintain their quality of life and go back to what they love doing after radiosurgery. Thanks to the very low dose delivered outside the target, it’s able to protect surrounding healthy tissue. Esprit takes Gamma Knife to the next level with improvements in both the patient and user experience." 

With a variety of innovations now available in a single platform, Esprit continues to offer clinicians the option of frameless or frame-based workflows with a frame that provides superior visualization. Remote accessibility and collaboration tools for the treatment team are designed to meet the needs of changing environments. Esprit provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery

Leksell Gamma Knife has over 50 years of clinical evidence and remains the gold standard of intracranial radiosurgery. The U.S. has the largest installed base of Gamma Knife systems, whose users have contributed to driving the standard of care forward. Continuous advances in its design have resulted in extremely fast automated treatment planning for clinicians, and Esprit is ideal for safely treating a broad range of indications, including multiple metastases, arteriovenous malformations, trigeminal neuralgia and vestibular schwannoma. 

For more information: www.elekta.com/elekta-esprit 

*Elekta Esprit is CE marked and FDA 510(k) cleared, with limited global availability. 


Related Content

News | Radiation Oncology

November 28, 2022 — Dunlee unveiled its new oncology bundles in the U.S. for the first time at Radiological Society of ...

Time November 28, 2022
arrow
News | RSNA | By Christine Book

November 27, 2022 — Among dozens of technical exhibit visits, informative discussions, and captivating Plenary Session ...

Time November 27, 2022
arrow
Videos | ASTRO

Dr. Frank A. Vicini, MD, FACR, FASTRO, FABS, who is a radiation oncologist with GenesisCare, discussed his findings from ...

Time November 09, 2022
arrow
News | Artificial Intelligence

Nov. 4, 2022 — Guerbet announced an agreement with Merative formalizing the termination of their collaboration initiated ...

Time November 05, 2022
arrow
News | Artificial Intelligence

Nov. 4, 2022 — The U.S. Food and Drug Administration (FDA) is recommending health care providers discuss alternative ...

Time November 05, 2022
arrow
News | Proton Therapy

November 3, 2022 — Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation ...

Time November 03, 2022
arrow
Feature | Lung Imaging | By Christine Book

The pace of new lung cancer screening initiatives, published research and collective efforts of organizations and ...

Time November 03, 2022
arrow
Feature | ASTRO | Christine Book

November 2, 2022 — The Imaging Technology News (ITN) editorial team is pleased to present the second portion of the ...

Time November 02, 2022
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a rundown of what you and your colleagues found to be most interesting in the field of medical imaging during ...

Time November 01, 2022
arrow
Subscribe Now